High Content Analysis: Technologies, Applications, Market Analysis

Table of Contents

Chapter 1

• INTRODUCTION
• 1.1. HCA Defined
• 1.2. Similarities Between HCA and high-throughput screening
• 1.3. Overlap Between HCA and HTS
  • One Group' s Experience

Chapter 2

• HCA: CURRENT STATE
• 2.1. Introduction
• 2.2. Use Categories
  • Primary Screening
  • Secondary Screening and Toxicology
• 2.3. Live-Cell Analysis
  • Kinetic Analyses vs. Fixed-Cell Analyses
• 2.4. Common Applications
• 2.5. Common Assays
• 2.6. Imaging Consideration
• 2.7. Confocal Instruments
• 2.8. New Developments
  • Assays and Kits
• 2.9. Software Challenges
  • 3D and 4D Image Analysis
• 2.10. A Third-Party Software Provider' s Perspective
• 2.11. Data Standardization

Chapter 3

• COMPANIES, TRENDS, AND MARKETS
• 3.1. Leaders
• 3.2. Trends
• 3.3. HCA vs. HTS
• 3.4. Barriers to Entry
• 3.5. Technology Wishes
  • Caliper and Microfluidics

Chapter 4

• HCA MARKET ANALYSIS
• 4.1. Main Drivers and Barriers
• 4.2. Position of Dominant Players
  • An Emerging Market for Kits and Assays
• 4.3. Analysis of Total Cost of Ownership
• 4.4. Analysis of HCA Applications
  • Emergence of the Academic Market
• 4.5. Market Dynamics: Big Fish Eating Little Fish

APPENDIX

• CHI INSIGHT PHARMA REPORTS - HIGH-CONTENT ANALYSIS SURVEY - MARCH 2007

REFERENCES

COMPANY INDEX WITH WEB ADDRESSES

EXPERTS INTERVIEWED FOR THIS REPORT

• Andrea Chow, vice president of microfluidics R&D, Caliper Life Sciences
• Cathy Howat, marketing director for InCell Analyzer in Europe, GE Healthcare
• Mark Collins, marketing manager, cellular imaging and analysis business, Cellomics
• Peter O' Brien, University College Dublin
• Anthony Davies, Institute of Molecular Medicine, Trinity College, Dublin
• Jason Swedlow, University of Dundee, Open Microscopy Environment
• Nick Arini, product marketing manager Definiens
• Kurt Herrenknecht, business development, Europe, Evotec
• Ralph Garippa, research leader, Roche Discovery Technologies